Semaxanib

Generic Name: Semaxanib

Brand Names: -

Drug Type: Small Molecule

Chemical Formula: C_₁₅H_₁₄N_₂O

CAS Number: 194413-58-6

Unique Ingredient Identifier: 71IA9S35AJ

Indication: Investigated for use/treatment in colorectal cancer and lung cancer.

Associated Conditions: -

Associated Therapies: -

Clinical Trials

SU5416 Combined With Gemcitabine and Cisplatin in Treating Patients With Advanced Solid Tumors

Phase 1

Conditions: Unspecified Adult Solid Tumor, Protocol Specific

First Posted Date: 2004-07-19

Last Posted Date: 2013-12-19

Lead Sponsor: Jonsson Comprehensive Cancer Center

Registration Number: NCT00005996

SU5416 in Treating Patients With AIDS-Related Kaposi's Sarcoma

Phase 2

Completed

Conditions: Sarcoma

First Posted Date: 2004-07-19

Last Posted Date: 2014-08-29

Lead Sponsor: AIDS Malignancy Consortium

Registration Number: NCT00005042

Locations: 🇺🇸
Memorial Sloan-Kettering Cancer Center, New York, New York, United States
🇺🇸
UCLA Clinical AIDS Research and Education (CARE) Center, Los Angeles, California, United States

SU5416 in Treating Patients With AIDS-Related Kaposi's Sarcoma

Phase 1

Completed

Conditions: Sarcoma

First Posted Date: 2004-06-16

Last Posted Date: 2012-08-23

Lead Sponsor: Pfizer

Registration Number: NCT00003720

Locations: 🇺🇸
USC/Norris Comprehensive Cancer Center, Los Angeles, California, United States
🇺🇸
Kaplan Cancer Center, New York, New York, United States
🇺🇸
Jonsson Comprehensive Cancer Center, UCLA, Los Angeles, California, United States

and more 1 locations

SU5416 in Treating Patients With Metastatic or Locally Recurrent Colorectal Cancer

Phase 2

Terminated

Conditions: Colorectal Cancer

Interventions: Drug: semaxanib

First Posted Date: 2004-05-26

Last Posted Date: 2013-06-03

Lead Sponsor: National Cancer Institute (NCI)

Target Recruit Count: 37

Registration Number: NCT00006001

Locations: 🇺🇸
University of Illinois at Chicago, Chicago, Illinois, United States
🇺🇸
University of Chicago Cancer Research Center, Chicago, Illinois, United States
🇺🇸
Louis A. Weiss Memorial Hospital, Chicago, Illinois, United States

and more 7 locations

Liposomal Daunorubicin and SU5416 in Treating Patients With Hematologic Cancer That Has Not Responded to Initial Therapy

Phase 1

Completed

Conditions: Chronic Myelomonocytic Leukemia
Previously Treated Myelodysplastic Syndromes
Recurrent Adult Acute Myeloid Leukemia
Refractory Anemia With Excess Blasts
Refractory Anemia With Excess Blasts in Transformation

Interventions: Drug: liposomal daunorubicin citrate
Drug: semaxanib
Other: laboratory biomarker analysis

First Posted Date: 2004-05-26

Last Posted Date: 2013-01-23

Lead Sponsor: National Cancer Institute (NCI)

Target Recruit Count: 37

Registration Number: NCT00005942

Locations: 🇺🇸
M D Anderson Cancer Center, Houston, Texas, United States

Leucovorin and Fluorouracil With or Without SU5416 in Treating Patients With Metastatic Colorectal Cancer

Phase 3

Completed

Conditions: Colorectal Cancer

First Posted Date: 2004-04-19

Last Posted Date: 2012-09-11

Lead Sponsor: Pfizer

Registration Number: NCT00004252

Locations: 🇺🇸
Tower Hematology Oncology Medical Group, Los Angeles, California, United States
🇺🇸
Raleigh Hematology/Oncology Associates - Wake Practice, Raleigh, North Carolina, United States
🇺🇸
APN-IMPATH Research Corporation, Fort Lee, New Jersey, United States

and more 23 locations

Combination Chemotherapy With or Without SU5416 in Treating Patients With Metastatic Colorectal Cancer

Phase 3

Conditions: Colorectal Cancer

First Posted Date: 2004-04-13

Last Posted Date: 2013-12-19

Lead Sponsor: Jonsson Comprehensive Cancer Center

Registration Number: NCT00021281

Locations: 🇺🇸
Jonsson Comprehensive Cancer Center, UCLA, Los Angeles, California, United States

SU5416, Irinotecan, and Cisplatin in Treating Patients With Advanced Solid Tumors

Phase 1

Completed

Conditions: Unspecified Adult Solid Tumor, Protocol Specific

First Posted Date: 2004-03-05

Last Posted Date: 2013-01-31

Lead Sponsor: Ohio State University Comprehensive Cancer Center

Registration Number: NCT00006000

Locations: 🇺🇸
Arthur G. James Cancer Hospital - Ohio State University, Columbus, Ohio, United States

SU5416 in Treating Patients With Malignant Mesothelioma

Phase 2

Completed

Conditions: Malignant Mesothelioma

Interventions: Drug: semaxanib

First Posted Date: 2004-02-26

Last Posted Date: 2013-06-03

Lead Sponsor: National Cancer Institute (NCI)

Target Recruit Count: 45

Registration Number: NCT00006014

Locations: 🇺🇸
Division of Hematology/Oncology, Park Ridge, Illinois, United States
🇺🇸
Fort Wayne Medical Oncology and Hematology, Inc., Fort Wayne, Indiana, United States
🇺🇸
Michiana Hematology/Oncology P.C., South Bend, Indiana, United States

and more 7 locations

SU5416 in Treating Patients With Advanced, Metastatic, or Recurrent Soft Tissue Sarcomas

Phase 2

Completed

Conditions: Gastrointestinal Stromal Tumor
Sarcoma

Interventions: Drug: semaxanib

First Posted Date: 2004-02-12

Last Posted Date: 2013-02-11

Lead Sponsor: National Cancer Institute (NCI)

Target Recruit Count: 60

Registration Number: NCT00005862

Locations: 🇺🇸
Dana-Farber Cancer Institute, Boston, Massachusetts, United States
🇺🇸
Massachusetts General Hospital Cancer Center, Boston, Massachusetts, United States

Drug Development Updates

Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.

Home Terms & Conditions Privacy Policy